February 18, 2020Interactive Cardiovascular and Thoracic Surgery
Excellent long-term results with minimally invasive edge-to-edge repair in myxomatous degenerative mitral valve regurgitation
Key result
Minimally invasive mitral valve edge-to-edge repair for myxomatous degeneration showed excellent long-term durability, with a 16-year overall survival rate of 95.9% (95% CI 89.39-98.43).
Why the study?
Although minimally invasive mitral valve repairs showed excellent results up to 10 years, long-term durability beyond 10 years for edge-to-edge repair in myxomatous degeneration remained to be assessed.
Population
97 consecutive patients with severe myxomatous mitral regurgitation
Comparison
Mitral valve repair through a right minithoracotomy
Design
Consecutive cohort study
Follow-up
Median 15.5 years
Authors
Discussion
Loading...
Member takes
Implication
May support use in selected young patients with myxomatous MR; extends prior series but leaves open need for randomized confirmation.
Study Design
Type
Cohort (n=97)
Structured PICO
P
Population
97 consecutive patients (mean age 35 years) with severe myxomatous mitral regurgitation who underwent minimally invasive edge-to-edge repair, followed for a median of 15.5 years.
E
Exposure
Minimally invasive mitral valve edge-to-edge repair through a right minithoracotomy
O
Outcome
Long-term durability beyond 10 years, including overall survival, cardiac death, reoperation for recurrent severe MR, and recurrence of MR ≥3+hard clinical
Minimally invasive edge-to-edge repair for myxomatous mitral regurgitation demonstrates excellent durability and survival at over 15 years of follow-up.
Cite This Study
Belluschi et al. (2020) conducted a cohort in Severe myxomatous mitral regurgitation (n=97). Minimally invasive mitral valve edge-to-edge repair through a right minithoracotomy was evaluated on 16-year overall survival rate (95% CI 89.39-98.43). Minimally invasive mitral valve edge-to-edge repair for myxomatous degeneration showed excellent long-term durability, with a 16-year overall survival rate of 95.9% (95% CI 89.39-98.43).